All In Biotech

Drug Trial Radar · NCT01872689

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 505 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

505

Actual

Start

Oct 13, 2013

Primary completion

Jul 28, 2017

Study completion Nov 6, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • LebrikizumabDrug

    Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.

  • PirfenidoneDrug

    Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.

  • PlaceboDrug

    Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 WeeksTime frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)

Locations

112 sites in 13 countries. Site status is shown where the registry gives one.

  • University Alabama At Birmingham

    Birmingham, Alabama

  • Mayo Clinic- Scottsdale

    Scottsdale, Arizona

  • Southern Arizona Veterans Administration Healthcare Systems

    Tucson, Arizona

  • University of Arizona

    Tucson, Arizona

  • UCSD Medical Center

    La Jolla, California

  • University of California, San Francisco

    San Francisco, California

  • National Jewish Health

    Denver, Colorado

  • Rocky Mountain Center For Clinical Research

    Wheat Ridge, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Research Alliance Inc

    Clearwater, Florida

  • Mayo Clinic-Jacksonville

    Jacksonville, Florida

  • University Miami

    Miami, Florida

  • Central Florida Pulmonary Group, PA

    Orlando, Florida

  • USF Tampa General Hospital

    Tampa, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Piedmont Healthcare Pulmonary and Critical Care Research

    Austell, Georgia

  • Southeastern Lung Care

    Decatur, Georgia

  • University of Chicago; Pulmonary and Critical Care

    Chicago, Illinois

  • Loyola University Med Center

    Maywood, Illinois

  • Univ of Iowa Hosp & Clinics; Pulmonary

    Iowa City, Iowa

  • Uni of Kansas Medical Center

    Kansas City, Kansas

  • Via Christi Hospital Inc. DBA Via Christi Research; Research Dept.

    Wichita, Kansas

  • Maine Medical Center -Division of Pulmomary and Critical Care Medicine

    Portland, Maine

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Johns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • University of Minnesota Hospital & Clinic

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Cardiopulmonary Associates LLC Cardiopulmonary Research

    Chesterfield, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Lovelace Scientific Resources, Inc.

    Albuquerque, New Mexico

  • Weill Medical College of Cornell University

    New York, New York

  • Mt Sinai School Medical Pulmo And Critical Care Med

    New York, New York

  • Highland Hospital-University of Rochester Medical Center

    Rochester, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Case Western Research University; University Hospitals Case Medical Center

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oklahoma University Health Sciences Center

    Oklahoma City, Oklahoma

  • The Oregon Clinic.

    Portland, Oregon

  • Penn State University College Medical Allergy And Care Med

    Hershey, Pennsylvania

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.